Literature DB >> 14638547

Milrinone facilitates resuscitation from cardiac arrest and attenuates postresuscitation myocardial dysfunction.

James T Niemann1, Daniel Garner, Emad Khaleeli, Roger J Lewis.   

Abstract

BACKGROUND: Left ventricular (LV) dysfunction with a low cardiac index after successful CPR contributes to early death attributable to multiorgan failure, and an effective treatment has not been identified. The purpose of this study was to investigate the use of milrinone, a selective phosphodiesterase III inhibitor, as treatment for LV dysfunction after resuscitation. METHODS AND
RESULTS: Ventricular fibrillation (VF) was induced electrically in 32 swine. After 5 minutes of VF, CPR was initiated and animals were randomized to receive either saline (control group, n=16) as a bolus and infusion or milrinone 50 microg/kg as a bolus and then 0.5 microg/kg per min for 60 minutes (treatment group, n=16). After 2 minutes of CPR (total VF time, 7 minutes), countershocks were given. Coronary perfusion pressures during CPR were similar for the groups (24+/-2 versus 21+/-4 mm Hg). All animals were defibrillated; 6 of 16 control animals developed refractory postcountershock pulseless electrical activity compared with 0 of 16 treated animals (P=0.018). At 30 minutes after restoration of spontaneous circulation, stroke volume (16+/-3 versus 26+/-7 mL, P<0.01) and LV dp/dt (793+/-197 versus 1108+/-316 mm Hg/s, P<0.02) were higher in the treatment group. Similar differences were observed 60 minutes after restoration of spontaneous circulation. Significant differences in heart rates between groups were not observed, and peripheral vascular resistance was significantly greater in the control group 30 and 60 minutes after resuscitation.
CONCLUSIONS: Milrinone facilitates resuscitation from prolonged VF and attenuates LV dysfunction after resuscitation without worsening major determinants of myocardial oxygen demand.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638547     DOI: 10.1161/01.CIR.0000101925.37174.85

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  Pediatric cardiopulmonary resuscitation: advances in science, techniques, and outcomes.

Authors:  Alexis A Topjian; Robert A Berg; Vinay M Nadkarni
Journal:  Pediatrics       Date:  2008-11       Impact factor: 7.124

2.  Infliximab attenuates early myocardial dysfunction after resuscitation in a swine cardiac arrest model.

Authors:  James T Niemann; Scott Youngquist; John P Rosborough; Atman P Shah; Quynh T Phan; Scott G Filler
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

Review 3.  Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest.

Authors:  Raúl J Gazmuri; Jeejabai Radhakrishnan
Journal:  Crit Care Clin       Date:  2012-04       Impact factor: 3.598

4.  Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts.

Authors:  Shuhei Matsumoto; Sungsam Cho; Shinya Tosaka; Ushio Higashijima; Takuji Maekawa; Tetsuya Hara; Koji Sumikawa
Journal:  Cardiovasc Diabetol       Date:  2012-01-12       Impact factor: 9.951

Review 5.  Myocardial Dysfunction and Shock after Cardiac Arrest.

Authors:  Jacob C Jentzer; Meshe D Chonde; Cameron Dezfulian
Journal:  Biomed Res Int       Date:  2015-09-02       Impact factor: 3.411

6.  Pretreatment with a Phosphodiesterase-3 Inhibitor, Milrinone, Reduces Hepatic Ischemia-Reperfusion Injury, Minimizing Pericentral Zone-Based Liver and Small Intestinal Injury in Rats.

Authors:  Shinichi Nakanuma; Hidehiro Tajima; Hiroyuki Takamura; Seisho Sakai; Ryosuke Gabata; Mitsuyoshi Okazaki; Hiroyuki Shinbashi; Yoshinao Ohbatake; Isamu Makino; Hironori Hayashi; Tomoharu Miyashita; Sachio Fushida; Tetsuo Ohta
Journal:  Ann Transplant       Date:  2020-07-14       Impact factor: 1.530

7.  Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model.

Authors:  Shih-Ni Wu; Min-Shan Tsai; Chien-Hua Huang; Wen-Jone Chen
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.